OPKO HEALTH, INC. (OPK) Form 8-K — Jul 27, 2026
OPKO Health reported second quarter 2026 revenue of $163.5 million, an increase from $156.8 million in the prior-year period, driven by intellectual property transfers and product sales. The company significantly narrowed its net loss to $8.4 million, or $0.01 per share, compared to a net loss of $148.4 million, or $0.19 per share, in the second quarter of 2025. OPKO ended the quarter with $314.4 million in cash and equivalents and provided full-year 2026 revenue guidance of $560 million to $585 million. The company repurchased $13.2 million of common stock during the quarter under an authorization that began in July 2025.
Key figures
- Revenue
- 163500000
- Guidance
- $560 million - $585 million
- Cash Position
- 314400000
- Repurchase Amount Q2
- 13200000
- Entera Private Placement
- 275000000
- Nicoya Milestone Potential
- 115000000
Price after filing
Close on the filing date to close N calendar days later (from $1.17). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.